Shenyang Xingqi Pharmaceutical Co., Ltd. (hereinafter referred to as “Xingqi Pharmaceutical”) is a state-level high-tech company located in Qipan Mountain, Shenyang City. It covers a floor area of about 76,000 square meters, and specializes in the R & D, production and sales of ophthalmic medications.The company went public on the ChiNext of Shenzhen Stock Exchange (Stock: Xingqi Ophthalmic Medications; Stock Code: 300573) on December 8, 2016.Driven by the vision of “growing into a globally competitive ophthalmic medication researcher and manufacturer,” Xingqi has been committed to the mission of promoting health and improving vision and has been truly honoring the company values - responsibility, refinement, perseverance, innovation, and devotion – in services for the eye care industry.At present, the company provides more than ten categories of quality ophthalmic medications including ophthalmic anti-infectives, ophthalmic anti-inflammatory agents, artificial tears and eye lubricants, dry eye medications and nutrition and corneal repair medications, mydriatics and cycloplegia drugs, ophthalmic non-steroidal anti-inflammatory drugs, miotics and anti-glaucoma drugs and intraoperative intraocular irrigation fluids.
Innovation is the driving force for Xingqi Pharmaceutical to grow from strength to strength. The company has established the Liaoning Province Enterprise Technology Center, Liaoning Province Ophthalmic Medication Technology Innovation Center and Liaoning Province Children and Adolescents Myopia Prevention and Control Engineering Research Center. It has also established an ophthalmic drug R & D platform for conventional ophthalmic preparations, instant gels, sustained-release preparations, GLP, drug packaging materials and has developed comprehensive capabilities for ophthalmic medication R & D and innovation. In October 2020, CNAS accredited the Quality Inspection Center of Xingqi in acknowledgement of its expertise in undertaking experiments and tests that meet the recognized standards.
Quality by Design and fastidious attention to details are essential to quality products of Xingqi. The Qipan Mountain Factory of Xingqi Pharmaceutical was put into production in 2014. It was designed in accordance with US FDA and EU GMP standards and was jointly founded by world-class design team, equipment suppliers and construction companies. It has production lines for calf blood extractives, single-dose eye drops, multi-dose eye drops, ophthalmic gel, ophthalmic solution and inner packaging materials for ophthalmic medications that are up to China’s GMP standards.
Xingqi Pharmaceutical focuses on ophthalmic drug R & D and production, takes a market-oriented approach and works closely with Chinese and international research institutions, medical institutions and ophthalmology experts to accelerate the transformation of scientific research results. Through academic advancement the company has optimized marketing. Based on a comprehensive marketing system, the company has partnered with distributors at various levels and has extended its sales network across provincial, municipal and county-level medical institutions throughout China.
Changes and improvements never end at Xingqi Pharmaceutical, which goes all out to create long-term values for customers, employees, shareholders, partners and the society and shoulders the mission of promoting Chinese medicine based on continuous self-improvement. Xingqi will keep forging ahead steadfastly to realize the vision of “growing into a globally competitive ophthalmic medication researcher and manufacturer”.